An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
A phase 3 trial of Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab and Enfortumab vedotin in bladder & urothelial cancer, run by AstraZeneca, now recruiting.
Overview
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC is a phase 3 interventional study registered as NCT07720284 by AstraZeneca, with 915 participants planned, started 2026-07-16 and due to reach its primary completion in 2030-09-11. Interventions recorded: Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab and Enfortumab vedotin.
Similar pages
not linked directly; found by shared links- TrialTreatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Shares Enfortumab vedotin, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Shares Rilvegostomig, AstraZeneca, Pembrolizumab and the tag pipeline.
- TrialA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Shares Rilvegostomig, Durvalumab, AstraZeneca and the tag pipeline.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Rilvegostomig, Durvalumab, AstraZeneca and the tag pipeline.
- TrialA Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Shares Daiichi Sankyo, Durvalumab, AstraZeneca, Pembrolizumab and the tag pipeline.